- Home
- AEMD vs JAGX Comparison
AEMD vs JAGX Comparison
Compare AEMD & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEMD
- JAGX
- Stock Information
- Founded
- AEMD 1984
- JAGX 2013
- Country
- AEMD United States
- JAGX United States
- Employees
- AEMD N/A
- JAGX N/A
- Industry
- AEMD Medical/Dental Instruments
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- AEMD Health Care
- JAGX Health Care
- Exchange
- AEMD Nasdaq
- JAGX Nasdaq
- Market Cap
- AEMD 7.3M
- JAGX 7.4M
- IPO Year
- AEMD N/A
- JAGX N/A
- Fundamental
- Price
- AEMD $0.40
- JAGX $5.88
- Analyst Decision
- AEMD Strong Buy
- JAGX
- Analyst Count
- AEMD 1
- JAGX 0
- Target Price
- AEMD $7.00
- JAGX N/A
- AVG Volume (30 Days)
- AEMD 157.3K
- JAGX 247.5K
- Earning Date
- AEMD 06-26-2025
- JAGX 05-15-2025
- Dividend Yield
- AEMD N/A
- JAGX N/A
- EPS Growth
- AEMD N/A
- JAGX N/A
- EPS
- AEMD N/A
- JAGX N/A
- Revenue
- AEMD N/A
- JAGX $11,689,000.00
- Revenue This Year
- AEMD N/A
- JAGX $22.41
- Revenue Next Year
- AEMD N/A
- JAGX $30.00
- P/E Ratio
- AEMD N/A
- JAGX N/A
- Revenue Growth
- AEMD N/A
- JAGX 19.75
- 52 Week Low
- AEMD $0.24
- JAGX $4.02
- 52 Week High
- AEMD $1.79
- JAGX $502.50
- Technical
- Relative Strength Index (RSI)
- AEMD 54.61
- JAGX 37.09
- Support Level
- AEMD $0.35
- JAGX $5.30
- Resistance Level
- AEMD $0.44
- JAGX $13.20
- Average True Range (ATR)
- AEMD 0.04
- JAGX 1.49
- MACD
- AEMD 0.00
- JAGX -0.57
- Stochastic Oscillator
- AEMD 62.70
- JAGX 7.30
About AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.